We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Epidemiologic Registry PETHEMA LMA 2015

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02607059
Recruitment Status : Recruiting
First Posted : November 17, 2015
Last Update Posted : March 23, 2021
Information provided by (Responsible Party):
PETHEMA Foundation

Brief Summary:
Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary acute myeloid leukemia (AML) in the PETHEMA Group institutions. This study is a non-interventional research regarding diagnosis and therapeutic approach

Condition or disease Intervention/treatment
AML Other: Registry

Detailed Description:
To perform this registry, every patient diagnosed with AML in the participant institutions, regardless type of AML and treatment administered, must be reported. It will be required to registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice of the centers. The treatment which has been administered by every center of the PETHEMA Group, even when it is considered as supportive care, and evolution of the disease will also be reported (relapse o death). PETHEMA Group will input all the reported information in data bases

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 500 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2015)
Actual Study Start Date : May 2015
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Primary Outcome Measures :
  1. characteristics of the patients diagnosed of AML [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with acute myeloid leukemia

Inclusion Criteria:

  • Patients diagnosed with acute myeloid leukemia

Exclusion Criteria:

  • No exclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02607059

Layout table for location contacts
Contact: Pau Montesinos, Dr montesinos_pau@gva.es

Layout table for location information
Hospital La Fe Recruiting
Valencia, Spain
Contact: Pau Montesinos, Dr       montesinos_pau@gva.es   
Sponsors and Collaborators
PETHEMA Foundation
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: PETHEMA Foundation
ClinicalTrials.gov Identifier: NCT02607059    
Other Study ID Numbers: LAM 2015
First Posted: November 17, 2015    Key Record Dates
Last Update Posted: March 23, 2021
Last Verified: March 2021